生物制药与制药应用

Illumina药物开发解决方案

上市后:IIT研究者发起研究

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
  • 影响因子:54.433
  • 文献链接:The Lancet Oncology 21.2 (2020): 294-305;PMID: 31952975
  • 研究单位:MD Anderson Cancer Center,美国MD安德森癌症中心
  • 药企:Regeneron Pharmaceuticals
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
  • 影响因子:176.079
  • 文献链接:New England Journal of Medicine 2022 May 26;386(21):1973-1985;PMID: 35403841
  • 研究单位:Johns Hopkins Kimmel Cancer Center,美国约翰霍普金斯大学癌症中心
  • 药企:Bristol Myers Squibb
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
  • 影响因子:12.469
  • 文献链接:Journal for Immunotherapy of Cancer 2021 Oct;9(10):e00349;PMID: 34607899
  • 研究单位:Copenhagen University Hospital,丹麦哥本哈根大学附属医院
Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
  • 影响因子:12.469
  • 文献链接:Journal for Immunotherapy of Cancer 2022 May;10(5):e004329;PMID: 35550553
  • 研究单位:Radboud University Medical Center,荷兰拉德堡大学医学中心
HER3 augmentation via blockade of EGFR/AKT signaling enhances anticancer activity of HER3-targeting Patritumab Deruxtecan in EGFR-mutated non-small cell lung cancer
  • 影响因子:13.8
  • 文献链接:Clinical Cancer Research 28.2 (2022): 390-403;PMID: 34921025
  • 研究单位:Kindai University Faculty of Medicine and Daiichi Sankyo,近畿大学大学医学院+第一三共公司
First-in-class anti-immunoglobulin-like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors
  • 影响因子:13.8
  • 文献链接:Clinical Cancer Research 28.1 (2022): 57-70;PMID: 34598945
  • 研究单位:University of Toronto and Merck Inc,加拿大多伦多大学+默克公司